February 01, 2020

To
The Manager, Listing Department
National Stock Exchange of India
Plot no. C/1 G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai- 400 051
Symbol: BLISSGVS

To
The General Manager, Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 506197

Dear Sir/Madam,

Subject: Newspaper Advertisement for transfer of unclaimed interim dividend and corresponding equity shares to Investor Education and Protection Fund (IEPF) Authority for the financial year 2012-13

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of the newspaper notice published in The Free Press Journal (English) and Navshakti (Regional) newspapers on February 01, 2020 for attention of Shareholders in respect of transfer of unclaimed interim dividend and corresponding equity shares of the Company to Investor Education and Protection Fund ("IEPF") for the financial year 2012-2013 in accordance with the provisions of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time.

The aforesaid advertisement is also available on the website of the Company at www.blissgvs.com.

Thanking you.

Yours faithfully,
For Bliss GVS Pharma Limited

[Signature]
Aditi Bhatt
Company Secretary

Encl: a/a
NOTICE

TRANSFER OF EQUITY SHARES & UNCLAIMED DIVIDEND TO INVESTOR EDUCATION & PROTECTION FUND (IEPF) ACCOUNT

This Notice is given pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 as amended from time to time thereafter ("the Rules"), the Interim dividend declared during the financial year 2012-13, which remain unclaimed for a period of seven years will be due to credit on March 22, 2020 to IEPF. The corresponding shares on which dividend was unclaimed for seven consecutive years will also be transferred to IEPF as per the procedure set out in the Rules.

The Company will not transfer such shares to the IEPF where there is a specific order of Court/tribunal restraining any transfer of such shares or where the shares are hypothecated/pledged under the Depositories Act, 1996.

In compliance to the Rules, the Company has communicated individually to the concerned shareholders whose shares are liable to be transferred to IEPF Account and the full details of such shares are made available on the Company's website at www.blissgvs.com. Shareholders concerned may refer to the said web-link to verify the details of their uncashed dividend and the corresponding shares liable to be transferred.

Shareholders are requested to claim the interim dividend declared during the financial year 2012-13 and onwards before the same is transferred to the IEPF.

The concerned shareholders holding shares in physical form and whose shares are liable to be transferred to IEPF may note that as per the requirement of the Rules, the Company would be issuing duplicate share certificate(s) in lieu of the original held by them for the purpose of transfer of shares to IEPF and upon such issue the Company shall inform the depository by way of corporate action to convert the duplicate share certificates into DEMAT form and transfer in favor of the IEPF. The original share certificate(s) which are registered in the name of original shareholders will stand automatically cancelled and be deemed non-negotiable. Concerned shareholders holding shares in dematerialized form may note that the Company shall inform the depository by way of corporate action for transfer of shares in favor of the DEMAT account of the IEPF.

In case the Company does not receive any communication from the concerned shareholders on or before March 21, 2020, the Company with a view to adhering with the requirements of the Rules, transfer the dividend to the IEPF on or after the due date i.e. March 22, 2020. The corresponding shares in which dividend is unclaimed for seven consecutive years shall also be transferred without any further notice.

Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF. Shareholders may claim the dividend and corresponding shares transferred to IEPF including all benefits accruing on such shares, if any, from the IEPF authorities after following the procedure prescribed in the Rules.

For any queries on the above matter, Shareholders are requested to contact the Company's Registrar and Share Transfer Agents, Universal Capital Securities Pvt. Ltd, 21/25 Shahid Nivas, Opp. Satya Sai Baba Temple, Mahakali Caves, Road, Andheri (East), Mumbai - 400093, Tel: 022-2820703-05, 28257441, Email: info@unisec.in.

FOR BLISS GVS PHARMA LIMITED

Sd/-

S. N. KAMATH
MANAGING DIRECTOR
This Notice is given pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 as amended from time to time thereafter (the Rules). The interim dividend declared during the financial year 2012-13, which remain unclaimed for a period of seven years will be due to credit on March 22, 2020 to IEPF. The corresponding shares on which dividend was unclaimed for seven consecutive years will also be transferred to IEPF as per the procedure set out in the Rules.

The Company will not transfer such shares to the IEPF where there is a specific order of Court/Tribunal restraining any transfer of such shares or where the shares are hypothecated/ pledges under the Depositories Act, 1996.

In compliance to the Rules, the Company has communicated individually to the concerned shareholders whose shares are liable to be transferred to IEPF Account and the full details of such shares are made available on the Company’s website at www.blissgvs.com. Shareholders concerned may refer to the said web-link to verify the details of their unencashed dividend and the corresponding shares liable to be transferred.

Shareholders are requested to claim the interim dividend declared during the financial year 2012-13 and onward before the same is transferred to the IEPF. The concerned shareholders holding shares in physical form and whose shares are liable to be transferred to IEPF may note that as per the requirement of the Rules, the Company would be issuing duplicate share certificate(s) in lieu of the original held by them for the purpose of transfer of shares to IEPF and upon such issue the Company shall inform the depository by way of corporate action to convert the duplicate shares certificate(s) into DEMAT form and transfer in favor of the IEPF. The original share certificate(s) which are registered in the name of original shareholders will stand automatically cancelled and deemed non-negotiable. Concerned shareholders holding shares in dematerialized form may note that the Company shall inform the depository by way of corporate action for transfer of shares in favor of the DEMAT account of the IEPF.

In case the Company does not receive any communication from the concerned shareholders on or before March 21, 2020, the Company with a view to adhering with the requirements of the Rules, transfer the dividend to the IEPF on or after the due date i.e. March 22, 2020. The corresponding shares on which dividend is unclaimed for seven consecutive years shall also be transferred without any further notice. Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF. Shareholders may claim the dividend and corresponding shares transferred to IEPF including all benefits accruing on such shares, if any, from the IEPF authorities after following the procedure prescribed in the Rules.

For any queries on the above matter, Shareholders are requested to contact the Company’s Registrar and Share Transfer Agents, Universal Capital Securities Pvt Ltd, 21/25 Shakti Niwas, Opp. Satya Sai Baba Temple, Mahakali Caves, Road, Andheri (East), Mumbai - 400093, Tel: 022-28207203-05; 28257641, Email: info@unisec.in.

FOR BLISS GVS PHARMA LIMITED

S. N. KAMATH
MANAGING DIRECTOR